Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma

Frontiers in Oncology

Volumn 5, Issue JUN, 2015, Pages

  Buczkowicz, Pawel ^a   Hawkins, Cynthia ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

ACVR1; DIPG; Glioblastoma; Glioma; H3F3A; Histone; K27M; Pediatric

Indexed keywords

EID: 84934291386     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00147     Document Type: Review

References (85)

1. Ramos A, Hilario A, Lagares A, Salvador E, Perez-Nunez A, Sepulveda J. Brainstem gliomas. Semin Ultrasound CT MR (2013) 34(2):104-12. doi:10.1053/j.sult.2013.01.001.
2. Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol (2014) 128(4):573-81. doi:10.1007/s00401-014-1319-6.
3. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol (2012) 124(3):439-47. doi:10.1007/s00401-012-0998-0.
4. Robison NJ, Kieran MW. Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol (2014) 119(1):7-15. doi:10.1007/s11060-014-1448-8.
5. Bailey S, Howman A, Wheatley K, Wherton D, Boota N, Pizer B, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy - results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer (2013) 49(18):3856-62. doi:10.1016/j.ejca.2013.08.006.
6. Bartels U, Wolff J, Gore L, Dunkel I, Gilheeney S, Allen J, et al. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro Oncol (2014) 16(11):1554-9. doi:10.1093/neuonc/nou091.
7. Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res (2013) 19(11):3050-8. doi:10.1158/1078-0432.CCR-13-0306.
8. Cohen KJ, Gibbs IC, Fisher PG, Hayashi RJ, Macy ME, Gore L. A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol (2013) 15(6):783-7. doi:10.1093/neuonc/not021.
9. Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJ. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev (2012) 38(1):27-35. doi:10.1016/j.ctrv.2011.06.007.
10. Janssens GO, Jansen MH, Lauwers SJ, Nowak PJ, Oldenburger FR, Bouffet E, et al. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys (2013) 85(2):315-20. doi:10.1016/j.ijrobp.2012.04.006.
11. Muller K, Schlamann A, Guckenberger M, Warmuth-Metz M, Gluck A, Pietschmann S, et al. Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group. Strahlenther Onkol (2014) 190(4):377-81. doi:10.1007/s00066-013-0513-0.
12. Okada K, Yamasaki K, Tanaka C, Fujisaki H, Osugi Y, Hara J. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors. Jpn J Clin Oncol (2013) 43(11):1073-9. doi:10.1093/jjco/hyt124.
13. Porkholm M, Valanne L, Lonnqvist T, Holm S, Lannering B, Riikonen P, et al. Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer (2014) 61(9):1603-9. doi:10.1002/pbc.25045.
14. Rizzo D, Scalzone M, Ruggiero A, Maurizi P, Attina G, Mastrangelo S, et al. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? J Chemother (2015) 27(2):106-10. doi:10.1179/1973947814Y.0000000228.
15. Roos DE, Smith JG. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma - a critique. Int J Radiat Oncol Biol Phys (1999) 44(3):493-5. doi:10.1016/S0360-3016(98)00553-7.
16. Veldhuijzen van Zanten SE, Jansen MH, Sanchez Aliaga E, van Vuurden DG, Vandertop WP, Kaspers GJ. A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. Expert Rev Anticancer Ther (2015) 15(2):157-64. doi:10.1586/14737140.2015.974563.
17. Zaghloul MS, Eldebawy E, Ahmed S, Mousa AG, Amin A, Refaat A, et al. Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol (2014) 111(1):35-40. doi:10.1016/j.radonc.2014.01.013.
18. Zaky W, Wellner M, Brown RJ, Bluml S, Finlay JL, Dhall G. Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab. Pediatr Hematol Oncol (2013) 30(7):623-32. doi:10.3109/08880018.2013.829895.
19. Freeman CR, Perilongo G. Chemotherapy for brain stem gliomas. Childs Nerv Syst (1999) 15(10):545-53. doi:10.1007/s003810050542.
20. Maria BL, Rehder K, Eskin TA, Hamed LM, Fennell EB, Quisling RG, et al. Brainstem glioma: I. Pathology, clinical features, and therapy. J Child Neurol (1993) 8(2):112-28. doi:10.1177/088307389300800203.
21. Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol (2006) 24(8):1266-72. doi:10.1200/JCO.2005.04.6599.
22. Albright AL, Price RA, Guthkelch AN. Brain stem gliomas of children. A clinicopathological study. Cancer (1983) 52(12):2313-9. doi:10.1002/1097-0142(19831215)52:12<2313::AID-CNCR2820521226>3.0.CO;2-I.
23. Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the children's cancer group. Neurosurgery (1993) 33(6):1026-9. doi:10.1227/00006123-199312000-00010.
24. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 482(7384):226-31. doi:10.1038/nature10833.
25. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 44(3):251-3. doi:10.1038/ng.1102.
26. Cage TA, Samagh SP, Mueller S, Nicolaides T, Haas-Kogan D, Prados M, et al. Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst (2013) 29(8):1313-9. doi:10.1007/s00381-013-2101-0.
27. Grill J, Puget S, Andreiuolo F, Philippe C, MacConaill L, Kieran MW. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer (2012) 58(4):489-91. doi:10.1002/pbc.24060.
28. Kieran MW. Time to rethink the unthinkable: upfront biopsy of children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). Pediatr Blood Cancer (2015) 62(1):3-4. doi:10.1002/pbc.25266.
29. MacDonald TJ. Diffuse intrinsic pontine glioma (DIPG): time to biopsy again? Pediatr Blood Cancer (2012) 58(4):487-8. doi:10.1002/pbc.24090.
30. Cheng Y, Ng HK, Zhang SF, Ding M, Pang JC, Zheng J, et al. Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol (1999) 30(11):1284-90. doi:10.1016/S0046-8177(99)90057-6.
31. Louis DN, Rubio MP, Correa KM, Gusella JF, von Deimling A. Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol (1993) 52(5):507-15. doi:10.1097/00005072-199309000-00009.
32. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, et al. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res (1997) 57(2):304-9.
33. Sure U, Ruedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, et al. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol (1997) 56(7):782-9. doi:10.1097/00005072-199707000-00004.
34. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell (2013) 155(2):462-77. doi:10.1016/j.cell.2013.09.034.
35. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 455(7216):1061-8. doi:10.1038/nature07385.
36. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 17(1):98-110. doi:10.1016/j.ccr.2009.12.020.
37. Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol (2010) 28(8):1337-44. doi:10.1200/JCO.2009.25.5463.
38. Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol (2011) 29(30):3999-4006. doi:10.1200/JCO.2011.35.5677.
39. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 28(18):3061-8. doi:10.1200/JCO.2009.26.7252.
40. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet (2014) 46(5):451-6. doi:10.1038/ng.2936.
41. Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet (2014) 46(5):457-61. doi:10.1038/ng.2925.
42. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet (2014) 46(5):444-50. doi:10.1038/ng.2938.
43. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet (2014) 46(5):462-6. doi:10.1038/ng.2950.
44. Ederveen TH, Mandemaker IK, Logie C. The human histone H3 complement anno 2011. Biochim Biophys Acta (2011) 1809(10):577-86. doi:10.1016/j.bbagrm.2011.07.002.
45. Liang ML, Ma J, Ho M, Solomon L, Bouffet E, Rutka JT, et al. Tyrosine kinase expression in pediatric high grade astrocytoma. J Neurooncol (2008) 87(3):247-53. doi:10.1007/s11060-007-9513-1.
46. Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat Genet (2014) 46(7):726-30. doi:10.1038/ng.2995.
47. Paugh BS, Zhu X, Qu C, Endersby R, Diaz AK, Zhang J, et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res (2013) 73(20):6219-29. doi:10.1158/0008-5472.CAN-13-1491.
48. Puget S, Philippe C, Bax DA, Job B, Varlet P, Junier MP, et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One (2012) 7(2):e30313. doi:10.1371/journal.pone.0030313.
49. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med (2002) 346(6):420-7. doi:10.1056/NEJMoa012224.
50. Aihara K, Mukasa A, Gotoh K, Saito K, Nagae G, Tsuji S, et al. H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro Oncol (2014) 16(1):140-6. doi:10.1093/neuonc/not144.
51. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 125(2):315-26. doi:10.1016/j.cell.2006.02.041.
52. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 454(7205):766-70. doi:10.1038/nature07107.
53. Reynolds N, Salmon-Divon M, Dvinge H, Hynes-Allen A, Balasooriya G, Leaford D, et al. NuRD-mediated deacetylation of H3K27 facilitates recruitment of Polycomb Repressive Complex 2 to direct gene repression. EMBO J (2012) 31(3):593-605. doi:10.1038/emboj.2011.431.
54. Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 14(2):92-107. doi:10.1038/nrc3655.
55. Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell (2013) 24(5):660-72. doi:10.1016/j.ccr.2013.10.006.
56. Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev (2013) 27(9):985-90. doi:10.1101/gad.217778.113.
57. Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT, Heguy A, et al. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol (2013) 23(5):558-64. doi:10.1111/bpa.12042.
58. Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM, et al. A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol (2014) 128(5):743-53. doi:10.1007/s00401-014-1338-3.
59. Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science (2013) 340(6134):857-61. doi:10.1126/science.1232245.
60. Akbari MR, Lepage P, Rosen B, McLaughlin J, Risch H, Minden M, et al. PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst (2014) 106(1):djt323. doi:10.1093/jnci/djt323.
61. Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H, et al. WIP1 phosphatase as a potential therapeutic target in neuroblastoma. PLoS One (2015) 10(2):e0115635. doi:10.1371/journal.pone.0115635.
62. Zajkowicz A, Butkiewicz D, Drosik A, Giglok M, Suwinski R, Rusin M. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients. Br J Cancer (2015) 112:1114-20. doi:10.1038/bjc.2015.79.
63. Kleiblova P, Shaltiel IA, Benada J, Sevcik J, Pechackova S, Pohlreich P, et al. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J Cell Biol (2013) 201(4):511-21. doi:10.1083/jcb.201210031.
64. Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat (2009) 30(3):379-90. doi:10.1002/humu.20868.
65. Petrie KA, Lee WH, Bullock AN, Pointon JJ, Smith R, Russell RG, et al. Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. PLoS One (2009) 4(3):e5005. doi:10.1371/journal.pone.0005005.
66. Song GA, Kim HJ, Woo KM, Baek JH, Kim GS, Choi JY, et al. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J Biol Chem (2010) 285(29):22542-53. doi:10.1074/jbc.M109.094557.
67. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol (1999) 1(1):44-51. doi:10.1215/15228517-1-1-44.
68. Rood BR, MacDonald TJ. Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. J Neurooncol (2005) 75(3):267-72. doi:10.1007/s11060-005-6749-5.
69. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 352(10):997-1003. doi:10.1056/NEJMoa043331.
70. Agnihotri S, Burrell K, Buczkowicz P, Remke M, Golbourn B, Chornenkyy Y, et al. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov (2014) 4(10):1198-213. doi:10.1158/2159-8290.CD-14-0157.
71. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 360(8):765-73. doi:10.1056/NEJMoa0808710.
72. Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol (2012) 124(5):615-25. doi:10.1007/s00401-012-1031-3.
73. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 22(4):425-37. doi:10.1016/j.ccr.2012.08.024.
74. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature (1990) 345(6274):458-60. doi:10.1038/345458a0.
75. Greider CW. Telomeres, telomerase and senescence. Bioessays (1990) 12(8):363-9. doi:10.1002/bies.950120803.
76. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 266(5193):2011-5. doi:10.1126/science.7605428.
77. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet (1996) 18(2):173-9. doi:10.1002/(SICI)1520-6408(1996)18:2<173::AID-DVG10>3.0.CO;2-3.
78. Barszczyk M, Buczkowicz P, Castelo-Branco P, Mack SC, Ramaswamy V, Mangerel J, et al. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Acta Neuropathol (2014) 128(6):863-77. doi:10.1007/s00401-014-1327-6.
79. Mangerel J, Price A, Castelo-Branco P, Brzezinski J, Buczkowicz P, Rakopoulos P, et al. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathol (2014) 128(6):853-62. doi:10.1007/s00401-014-1348-1.
80. Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 126(6):917-29. doi:10.1007/s00401-013-1198-2.
81. Caretti V, Bugiani M, Freret M, Schellen P, Jansen M, van Vuurden D, et al. Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathol (2014) 128(4):605-7. doi:10.1007/s00401-014-1307-x.
82. Sethi R, Allen J, Donahue B, Karajannis M, Gardner S, Wisoff J, et al. Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neurooncol (2011) 102(1):121-7. doi:10.1007/s11060-010-0301-y.
83. Yoshimura J, Onda K, Tanaka R, Takahashi H. Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. Neurol Med Chir (2003) 43(8):375-82. doi:10.2176/nmc.43.375.
84. Sufit A, Donson AM, Birks DK, Knipstein JA, Fenton LZ, Jedlicka P, et al. Diffuse intrinsic pontine tumors: a study of primitive neuroectodermal tumors versus the more common diffuse intrinsic pontine gliomas. J Neurosurg Pediatr (2012) 10(2):81-8. doi:10.3171/2012.3.PEDS11316.
85. Saratsis AM, Kambhampati M, Snyder K, Yadavilli S, Devaney JM, Harmon B, et al. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes. Acta Neuropathol (2014) 127(6):881-95. doi:10.1007/s00401-013-1218-2.